Table 2 Dialysis prescription and delivered treatment over two years, showing similar session parameters across groups, with higher blood flow and ultrafiltration volumes in the HDF group.
Characteristics | Total | HD | HDF | Test | p-value |
|---|---|---|---|---|---|
Patients | 286 | 144 | 142 | ||
Treatment Time (tHD) (min) ‡ Median [Q1-Q3] | 240.0 [236.7; 240.0] | 240.0 [236.7.0;240.0] | 240.0 [237.3;240.0] | Wilcoxon test | 0.945 |
QB (ml/min) Median [Q1-Q3] | 336.7 [301.0; 366.7] | 325.8 [300.0; 365.0] | 345.0 [313.3; 366.7] | Wilcoxon test | 0.038 |
QD (ml/min) Median [Q1-Q3] | 500 [500; 500] | 500 [500; 500] | 500 [500; 500] | ||
QSUB (ml/min) Median [Q1-Q3] | 89.0 [79.0;103.5] | NA | 89.0 [79.0;103.5] | ||
TOTAL QUF (ml/min) Median [Q1-Q3] | 14.7 [8.8;97.7] | 8.8 [7.2;10.8] | 97.7 [86.7;110.9] | Wilcoxon test | < 0.001 |
Weight Loss (Kg) Median [Q1-Q3] | 2.1 [1.6;2.6] | 2.1 [1.6;2.6] | 2.1 [1.6;2.6] | Wilcoxon test | 0.881 |
NET QUF (ml/min) Median [Q1-Q3] | 8.7 [7.2;10.9] | 8.8 [7.2;10.8] | 8.7 [7.1;11.1] | Wilcoxon test | 0.973 |
Total‡ Ultrafiltration Vol (L/ses) Median [Q1-Q3] | 3.3 [2.0;23.2] | 2.0 [1.6;2.6] | 23.2 [19.4;26.0] | Wilcoxon test | < 0.001 |
